Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02594696 · ClinicalTrials.gov registry record · NA

Proactive Psychiatry Consultation for Patients With Cancer and Severe Mental Illness

A NA study of Breast Cancer and Cancer, sponsored by Massachusetts General Hospital.

Completed
Registry status
NA
Development phase
30
Enrollment target
1
Study location

NCT02594696: Completed NA study of Breast Cancer and Cancer, sponsored by Massachusetts General Hospital.

NCT02594696 is a NA study of Breast Cancer and Cancer that has completed, run by Massachusetts General Hospital. The registered enrollment target is 30 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02594696, a NA study of Breast Cancer and Cancer, has completed, sponsored by Massachusetts General Hospital.

COMPLETED
Registry status
NA
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

Individuals with severe mental illness (SMI) including schizophrenia and bipolar disorder are dying younger than the general population; cancer is a leading cause of death in this population. People with SMI have higher rates of dying from breast, lung, and colon cancer, and disparities in treatment appear to be one contributing factor. Individuals with SMI may be diagnosed with more advanced stage cancer and less likely to receive stage-appropriate cancer treatment. Although collaborative care models integrating medical and psychiatric care have shown promise in other populations, the challenge of treating SMI and cancer is distinct and relatively understudied. Patients may have uncontrolled psychiatric symptoms that can impact their understanding of their diagnosis and treatment decisions. Oncologists have less training and inadequate time to address multiple unmet needs. Mental health care is frequently fragmented from cancer care. The investigators want to understand if it is helpful for patients with SMI to be connected to a psychiatrist and case manager when cancer is diagnosed. Optimizing psychiatric symptoms and facilitating communication between the patient, the oncology team, and mental health providers may improve care. The goal is to pilot a pragmatic intervention for patients with cancer and SMI that can be integrated into cancer care, is acceptable to patients and oncology clinicians, and may promote the delivery of stage-appropriate cancer treatment to an underserved population. Patients will be connected to a psychiatrist and case manager at cancer diagnosis who will follow the patient and communicate with the oncology team during the 12 week intervention. All participants will complete brief surveys at baseline, 4 weeks, and 12 weeks. Oncology clinicians will provide feedback about the intervention at 12 weeks. Cancer treatment received and healthcare utilization will be assessed at 6 months post-intervention.

Primary Outcome

Feasibility of participating in the intervention: * At least 75% of intervention participants complete the psychiatric diagnostic assessment and establish contact with the case manager * At least 75% of enrolled patients complete the patient-reported measures. Feasibility of enrollment process: • At least 50% of patients who are approached enroll in the intervention

Interventions

  • OTHER Proactive Psychiatry Consultation (PPC)

Study Locations (1)

Massachusetts

  • Massachusetts General Hospital - Boston

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2015-11-09
Est. Completion 2017-11-01
Phase NA
Massachusetts General Hospital

2,032 total trials

What the finished NCT02594696 record still lists

NCT02594696 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower).

The record links to 8 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Proactive Psychiatry Consultation (PPC) is the first listed.

NCT02594696 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT02594696 about?

NCT02594696 is a clinical study titled "Proactive Psychiatry Consultation for Patients With Cancer and Severe Mental Illness". Individuals with severe mental illness (SMI) including schizophrenia and bipolar disorder are dying younger than the general population; cancer is a leading cause of death in this population. People with SMI have higher rates of dying from breast, lung, and colon cancer, and disparities in treatment...

What is the current status of trial NCT02594696?

This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2015-11-09. Estimated completion is 2017-11-01.

What conditions does trial NCT02594696 study?

This clinical trial studies the following conditions: Breast Cancer, Cancer, Lung Cancer, Schizophrenia, Head and Neck Cancer.

What interventions are being tested in trial NCT02594696?

The interventions under investigation include: Proactive Psychiatry Consultation (PPC) (OTHER).

Who is sponsoring clinical trial NCT02594696?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02594696 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02594696's enrollment target sits among peer trials

30 955th of 1224 higher than 227 of 1,224 other Breast Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02594696, the US trial registry maintained by the National Library of Medicine. NCT02594696 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.